Oncology
🇪🇺 EMA Page 5EMA news and analysis for pharmaceutical BD, investment, and market access · 12 articles on this page
Global oncology market intelligence for pharma BD, investors, and analysts. Track drug approvals, clinical trials, and competitive landscapes.
Showing 49–60 of 94 articles
Biosimilar Oncology Antibodies: EMA Market Dynamics & Healthcare Impact
HTA Outcomes Oncology Drugs: EU Regulation Impact on Germany, France, Italy
EU HTA Regulation Impact: Effects on Rare Disease Drug Approvals & Market Access
HTA Outcomes Oncology Therapies: G-BA vs NICE Post-Brexit Analysis
Silexion Therapeutics Submits Phase 2/3 Trial Application for SIL204 KRAS-Targeted Pancreatic Cancer Treatment
EMA Conditional Approvals CAR-T: What You Need to Know on B-Cell Lymphomas
BioPharma Clinical Trials: Gene Therapy, Obesity, and Oncology Updates
ASCO 2026: Olverembatinib Data & Gastric Cancer Trial Updates
EU Market Access ADCs: NICE, G-BA & HAS Assessments of Trastuzumab Deruxtecan
EMA Issues Positive Opinion for Viatris' Palbociclib Generic Cancer Treatment
CAR-T Access EU Policy: Impact of Cross-Border Healthcare on Advanced Therapies
RenovoRx TAMP Therapy Platform Data Accepted for 2026 ASCO Presentation - Phase III TIGeR-PaC Trial Results